Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly called fatty liver, is not a liver problem alone—it is a systemic marker of insulin resistance. Often silent for years, MASLD signals elevated cardiometabolic, cognitive, and longevity risk long before abnormal liver enzymes or diabetes appear.

Hyperinsulinemia often precedes diabetes by decades, quietly driving heart disease, weight gain, hypertension, fatty liver disease, and accelerated aging—even when glucose levels appear normal. Early detection shifts care from reactive treatment to true prevention.